Printed from Voxsanity (voxsanity.com.au) — NCT06142617 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Lung Cancer
Phase 2 Lung Cancer Trial, Not Yet Recruiting
NCT06142617
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Adults aged 18 or older, of any sex
- People diagnosed with a specific type of advanced lung cancer (non-squamous non-small cell lung cancer, stage IV) confirmed by a lab test of tissue or cells
- People who have not yet received any cancer treatments such as targeted therapy, chemotherapy, or immunotherapy — those who have had surgery may still be considered
- People whose lung cancer has a specific gene change (EGFR exon 21 point mutation) confirmed by a gene test of tissue or blood, and whose tumour tests positive for a protein called PD-L1 (at least 1%) confirmed by a lab method called immunohistochemistry
- People who have at least one measurable area of cancer that can be tracked according to standard measurement guidelines (RECIST 1.1)
- People who are fully active or have only minor restrictions on physical activity, as measured by a standard medical scoring system (performance score of 0 or 1)
- People whose blood, kidney, and liver are functioning within acceptable levels as confirmed by specific lab tests (confirm with trial site for exact values)
- People who are expected to live at least 6 months
- Male participants who agree to use effective contraception and not donate sperm during the study and for at least 180 days after the last dose
- Female participants who are not pregnant or breastfeeding, and who either cannot become pregnant naturally, or who agree to use effective contraception during treatment and for at least 180 days after the last dose
- Female participants who are able to become pregnant must have a negative pregnancy test (blood or urine) within 72 hours before the first dose
- People who have read, understood, and signed the consent form approved by an independent ethics committee, before any trial procedures begin
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People who have had an active autoimmune disease requiring systemic treatment (such as disease-modifying drugs, steroids, or immune-suppressing medicines) within the past 2 years — note that certain hormone replacement therapies for thyroid, adrenal, or pituitary conditions are generally permitted (confirm with trial site)
- People who have a history of lung inflammation (non-infectious pneumonia or interstitial lung disease) that required steroid treatment, or who currently have these conditions
- People who have been previously diagnosed with an immune deficiency condition, such as immunoglobulin deficiency or aplastic anaemia
- People with a known history of HIV infection
- People with active hepatitis B (based on specific virus levels in the blood) or active hepatitis C infection
- People with a known history of active tuberculosis
- People who received a live or weakened (attenuated) vaccine within 30 days before the first dose — inactivated vaccines are generally permitted
- People who have had another cancer within the past year that requires treatment — certain skin cancers or non-invasive cancers that have been successfully treated may still be considered (confirm with trial site)
- People who have brain or nervous system metastases causing symptoms, or inflammation of the membranes around the brain or spinal cord
- People who have had a severe allergic reaction (level 3 or above) to any of the study drugs (pembrolizumab, pemetrexed, platinum-based drugs, or osimertinib) or their ingredients
- People with an active infection that requires systemic treatment
- People with other serious medical conditions that the trial doctor believes could put them at risk or interfere with the trial results — such as poorly controlled diabetes, liver failure, or significant mental illness
- People with a confirmed mental illness or substance use problem that would interfere with following the trial requirements
- People who are pregnant, planning to become pregnant, or breastfeeding at any point from the screening visit through to 180 days after the last dose
- People who have received a transplant of donated tissue or a solid organ
- People who are not able to attend regular follow-up visits
- People who are currently taking part in another clinical trial or who have used another experimental drug or device
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
1 December 2023
Est. completion
30 November 2027
Where this trial is recruiting
🇨🇳 China
Primary endpoints
progression free survival 1 (PFS1)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 1 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.